|
1
|
García-Claver A, Lorente M, Mur P, et al:
Gene expression changes associated with erlotinib response in
glioma cell lines. Eur J Cancer. 49:1641–1653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleihues P, Louis DN, Scheithauer BW, et
al: The WHO classification of tumors of the nervous system. J
Neuropathol Exp Neurol. 61:215–225. 2002.PubMed/NCBI
|
|
3
|
de Vries NA, Beijnen JH, Boogerd W and van
Tellingen O: Blood-brain barrier and chemotherapeutic treatment of
brain tumors. Expert Rev Neurother. 6:1199–1209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mark J, Westermark B, Pontén J and
Hugosson R: Banding patterns in human glioma cell lines. Hereditas.
87:243–260. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Couldwell WT, de Tribolet N, Antel JP,
Gauthier T and Kuppner MC: Adhesion molecules and malignant
gliomas: implications for tumorigenesis. J Neurosurg. 76:782–791.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khong A, Cleaver AL, Alatas MF, Wylie BC,
Connor T, Fisher SA, Broomfield S, Lesterhuis WJ, Currie AJ and
Lake RA: The efficacy of tumor debulking surgery is improved by
adjuvant immunotherapy using imiquimod and anti-CD40. BMC cancer.
14:9692014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chao LC, Juan WS, Chang CC, Tai SH, Chuang
MT, Sze CI and Lee EJ: Surgical debulking plus adjuvant
chemoradiotherapy of a huge basal ganglion nongerminomatous germ
cell tumor with long term survival. Int J Pediatr. 2:312014.
|
|
8
|
Bush S, Williams H, Aksu C, Rungruang B,
Macfee M and Ghamande S: PET probe-assisted surgical debulking in
patients with recurrent gynecologic tumors. Gynecol Oncol.
130:e111–e112. 2013. View Article : Google Scholar
|
|
9
|
Hochberg FH and Pruitt A: Assumptions in
the radiotherapy of glioblastoma. Neurol. 30:907–911. 1980.
View Article : Google Scholar
|
|
10
|
Berens ME, Rutka JT and Rosenblum ML:
Brain tumor epidemiology, growth and invasion. Neurosurg Clin N Am.
1:1–18. 1990.PubMed/NCBI
|
|
11
|
Cho KK, Mikkelsen T, Lee YJ, et al: The
role of protein kinase Calpha in U-87 glioma invasion. Int J Dev
Neurosci. 17:447–461. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Demuth T and Berens ME: Molecular
mechanisms of glioma cell migration and invasion. J Neurooncol.
70:217–228. 2004. View Article : Google Scholar
|
|
13
|
Holland EC: Glioblastoma multiforme: the
terminator. Proc Natl Acad Sci USA. 97:6242–6254. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slawińska-Brych A, Zdzisińska B and
Kandefer-Szerszeń M: Fluvastatin inhibits growth and alters the
malignant phenotype of the C6 glioma cell line. Pharmacol Rep.
66:121–129. 2014. View Article : Google Scholar
|
|
15
|
Hadjipanayis CG and Van Meir EG: Brain
cancer propagating cells: biology, genetics and targeted therapies.
Trends Mol Med. 15:519–530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hentschel SJ and Lang FF: Current surgical
management of glioblastoma. Cancer J. 9:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuffel MJ, Reid JM and Ames MM:
Anthracyclines and their C-13 alcohol metabolites: growth
inhibition and DNA damage following incubation with human tumor
cells in culture. Cancer Chemother Pharmacol. 30:51–57. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cersosimo RJ and Hong WK: Epirubicin: a
review of the pharmacology, clinical activity and adverse effects
of an adriamycin analogue. J Clin Oncol. 4:425–439. 1986.PubMed/NCBI
|
|
19
|
Bonadonna G, Gianni L, Santoro A, Bonfante
V, Bidoli P, Casali P, Demicheli R and Valagussa P: Drugs ten years
later: epirubicin. Ann Oncol. 4:359–369. 1993.PubMed/NCBI
|
|
20
|
Birtle AJ: Anthracyclines and
cardiotoxicity. Clin Oncol. 12:146–152. 2000.
|
|
21
|
Coukell AJ and Faulds D: Epirubicin. An
updated review of its pharmacodynamic and pharmacokinetic
properties and therapeutic efficacy in the management of breast
cancer. Drugs. 53:453–482. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Astner ST, Pihusch R, Nieder C, Rachinger
W, Lohner H, Tonn JC, Molls M and Grosu AL: Extensive local and
systemic therapy in extraneural metastasized glioblastoma
multiforme. Anticancer Res. 26:4917–4920. 2006.
|
|
23
|
Dhanikula RS, Argaw A, Bouchard JF and
Hildgen P: Methotrexate loaded polyether-copolyester dendrimers for
the treatment of gliomas: enhanced efficacy and intratumoral
transport capability. Mol Pharm. 5:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Parney IF and Chang SM: Current
chemotherapy for glioblastoma. Cancer J. 9:149–156. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reynolds B and Weiss S: Generation of
neurons and astrocytes from isolated cells of the adult mammalian
central nervous system. Science. 255:1707–1710. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ohgaki H and Kleihues P: Epidemiology and
etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferrara N: Vascular endothelial growth
factor: basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirano A, Shimizu T, Imamura H, et al: The
combination of epirubicin plus docetaxel as neoadjuvant
chemotherapy in locally-advanced breast cancer. Anticancer Res.
26:581–584. 2006.PubMed/NCBI
|
|
29
|
Tokudome N and Ito Y: Adjuvant
chemotherapy based on evidence-based medicine for breast cancer
patients. Japan J Cancer Chemother. 33:318–323. 2006.In
Japanese.
|
|
30
|
Schott B and Robert J: Comparative
activity of anthracycline 13-dihydrometabolites against rat
glioblastoma cells in culture. Biochem Pharmacol. 38:4069–4074.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cantoni O, Sestili P, Cattabeni F, Geroni
C and Giuliani F: Comparative effects of doxorubicin and
4′-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a
human tumor cell line. Cancer Chemo Pharmacol. 27:47–5. 1990.
View Article : Google Scholar
|
|
32
|
Hershman DL and Shao T: Anthracycline
cardiotoxicity after breast cancer treatment. Oncology (Williston
Park). 23:227–234. 2009.
|
|
33
|
O'Shaughnessy J, Twelves C and Aapro M:
Treatment for anthracycline-pretreated metastatic breast cancer.
Oncologist. 7(Suppl 6): 4–12. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vitvitsky VM: Erythrocytes as carriers of
anthracycline antibiotics in vitro and in vivo. erythrocyte
engineering for drug delivery and targeting. pp. 992002
|
|
35
|
Salvatorelli E, Guarnieri S, Menna P, et
al: Defective one- or two-electron reduction of the anticancer
anthracycline epirubicin in human heart. Relative importance of
vesicular sequestration and impaired efficiency of electron
addition. J Biol Chem. 281:10990–11001. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dulak J and Józkowicz A: Regulation of
vascular endothelial growth factor synthesis by nitric oxide: facts
and controversies. Antioxidants and redox signaling. 5:123–132.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gerber DE: Targeted therapies: a new
generation of cancer treatments. Am Fam Physician. 77:311–319.
2008.PubMed/NCBI
|
|
38
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hortobágyi G: Anthracyclines in the
treatment of cancer. An overview Drugs. 54(Suppl 4): 1–7. 1997.
|
|
40
|
Shibata T, Tamura M, Kabashima N, et al:
Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell
proliferation by mevalonic acid depletion in human mesangial cells.
Life Sci. 84:725–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takenaka M, Hirade K, Tanabe K, et al:
Simvastatin stimulates VEGF release via p44/p42 MAP kinase in
vascular smooth muscle cells. Biochem Biophys Res Commun.
301:198–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
